Some groups of drugs which use is associated with development of drug-induced atrial fibrillation
| Autor: | N. A. Arablinskiy, O. D. Ostroumova, M. S. Cherniaeva, D. A. Sychyov, D. I. Bakhteeva |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Sildenafil business.industry Azathioprine 030204 cardiovascular system & hematology Fingolimod Gastroenterology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Zoledronic acid chemistry Vardenafil Internal medicine Prednisolone medicine 030212 general & internal medicine Hexoprenaline business Stanozolol medicine.drug |
| Zdroj: | Medical alphabet. 1:20-28 |
| ISSN: | 2078-5631 |
| Popis: | Recently, more and more attention has been paid to the problem of drug‑induced (DI) atrial fibrillation (AF). It is known that the development of DI AFcan be associated with the intake of cardiovascular and anticancer drugs, drugs that affect the central nervous system or respiratory organs. However,there are other drugs that can provoke DI AF, which practitioners are less aware of. This article is a review of the current literature on DI AF associated withthe intake of other groups of drugs and individual drugs that are not included in the above groups. Analysis of the available literature has shown that theincidence of DI AF reaches 6.9% when taking zoledronic acid and 1.5% when taking alendronate, although data from different authors regarding thecausal relationship between bisphosphonate therapy and the development of AF are ambiguous. The use of high doses of glucocorticosteroids (at a dailydose of ≥ 7.5 mg in terms of prednisolone) is also associated with an increased risk of AF (OR = 6.07; 95% CI: 3.90–9.42). Treatment with non‑steroidal anti‑inflammatory drugs is also associated with a higher risk of developing DI AF compared to those who do not use it – the incidence rate is 1.17 (95% CI:1.10–1.24) for nonselective and 1.27 (95% CI: 1.20–1.34) for cyclooxygenase‑2 inhibitors. The literature contains a description of clinical cases of DI AF whiletaking immunosuppressants (azathioprine, methotrexate + etanercept, fingolimod, cyclosporine), drugs that affect the genitourinary system (vardenafil,sildenafil, yohimbine hydrochloride, hexoprenaline), local anesthetics, bupacaero testosterone, stanozolol, testosterone cypionate, nandrolone decanoateextraboline) and nicotine‑containing products (nicotine‑containing chewing gum). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|